Table 3.
The counts of peripheral blood mononuclear fractions, NK cell activity, and T lymphocytes proliferation in controls and pancreatic cancer patients
| Controls | Patients | |||
|---|---|---|---|---|
| Preoperative | Postoperative | |||
| PBMCs | (×106/ml) | 2.6 (1.3–4.8) | 2.2 (0.9–4.9) | 2.4 (1.3–4.9) |
| cDC1 | (×103/ml) | 8.6 (3.2–26.9) | 5.4 (1.2–21.5)* | 5.9 (0.9–18.9) |
| cDC2 | (×103/ml) | 3.6 (1.7–8.2) | 4.6 (1.6–16.2) | 4.0 (1.9–29.4) |
| Total cDCs | (×103/ml) | 14.7 (5.6–33.6) | 10.4 (3.4–32.0) | 9.3 (4.3–48.3) |
| cDC1/cDC2 | (Ratio) | 2.7 (1.0–5.0) | 1.1 (0.2–5.3)** | 1.3 (0.2–3.8) |
| NK cells | (×105/ml) | 1.8 (0.9–4.2) | 2.2 (0.5–6.5) | 3.4 (0.8–11.7) |
| CD4+ T lymphocytes | (×105/ml) | 7.6 (1.3–22.0) | 5.0 (0.4–12.0) | 4.4 (1.3–10.9) |
| CD8+ T lymphocytes | (×105/ml) | 2.3 (0.2–7.0) | 2.0 (0.6–4.5) | 1.7 (0.4–13.1) |
| CD4+/CD8+ | (Ratio) | 3.0 (0.8–9.7) | 2.3 (0.4–6.0) | 2.1 (0.5–12.7) |
| NK cell activity | (%) | 29.3 (5.4–58.2) | 26.0 (7.2–78.0) | 27.7 (11.4–45.7) |
| PHA | (×104 c.p.m.) | 4.8 (3.5–6.3) | 4.6 (3.9–6.0) | 4.8 (2.8–6.3) |
The data are expressed as median and range
PBMCs, peripheral blood mononuclear cells; DCs, dendritic cells; NK cells, natural killer cells; PHA, Proliferative response of T lymphocytes towards mitogen
Statistical significance was determined using the Mann–Whitney U test and the Wilcoxon signed-rank test. *P=0.01, **P<0.001 versus controls